Login / Signup

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.

Mark-David LevinArnon P KaterMattias MattssonSabina KerstingJuha RantiHoa Thi Tuyet TranKazem NasserinejadCarsten Utoft Niemann
Published in: BMJ open (2020)
ClinicalTrials.gov Registry (NCT03226301).
Keyphrases